ROYAL BANK OF CANADA - ALX ONCOLOGY HLDGS INC ownership

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ALX ONCOLOGY HLDGS INC
ValueSharesWeighting
Q3 2023$17,000
-43.3%
3,680
-8.0%
0.00%
Q2 2023$30,000
+500.0%
4,001
+226.6%
0.00%
Q1 2023$5,000
-83.9%
1,225
-55.6%
0.00%
Q4 2022$31,000
+1450.0%
2,762
+958.2%
0.00%
Q3 2022$2,000
+100.0%
261
+117.5%
0.00%
Q2 2022$1,000
-94.4%
120
-89.0%
0.00%
Q1 2022$18,000
-73.1%
1,089
-65.2%
0.00%
Q4 2021$67,000
+737.5%
3,133
+2800.9%
0.00%
Q3 2021$8,000
+700.0%
108
+369.6%
0.00%
Q2 2021$1,000
-99.0%
23
-98.3%
0.00%
Q1 2021$99,000
+4850.0%
1,347
+5080.8%
0.00%
Q4 2020$2,000260.00%
Other shareholders
ALX ONCOLOGY HLDGS INC shareholders Q4 2023
NameSharesValueWeighting ↓
venBio Partners LLC 9,699,925$109,318,15533.89%
Vivo Capital, LLC 4,220,048$47,5605.48%
Logos Global Management LP 2,349,600$26,479,9923.10%
Samsara BioCapital, LLC 262,786$2,961,5980.64%
Orbimed Advisors 2,871,000$32,356,1700.62%
Pier Capital, LLC 271,848$3,063,7270.50%
Cormorant Asset Management, LP 612,079$6,8980.46%
Nan Fung Group Holdings Ltd 41,950$472,7770.33%
Artal Group S.A. 500,000$5,6350.32%
Redmile Group, LLC 607,470$6,846,1870.28%
View complete list of ALX ONCOLOGY HLDGS INC shareholders